Although small molecules targeting REV1–REV7 interactions are effective in vitro and in vivo, an inhibitor targeting the global activity of REV7 may become another attractive tool for cancer therapy, because REV7 functions not only in TLS but also in other tumor-promoting conditions. The gene discussed is MAD2L2; the disease is cancer.